Boehringer Ingelheim Foundation.
A bridge to the future.
The Boehringer Ingelheim Foundation is an independent, non-profit foundation that is committed to promoting medical, biological, chemical, and pharmaceutical science.
Through our various activities, funding programmes, and scientific awards, we want to promote excellence in basic research in the natural and life sciences. One of our key objectives is to create the freedom scientists need to conduct outstanding research.
“We aim to create new prospects for excellent science and research, in part by supporting selected initiatives in our home region. But we also provide impulses for life sciences across Germany by supporting promising young group leaders with original and pioneering ideas.” Christoph Boehringer, Chairman of the Executive Committee, Boehringer Ingelheim Foundation, 2017
The funding of the Institute of Molecular Biology (IMB) at the University of Mainz is a milestone in the history of our Foundation. It bears witness to our aim of lastingly supporting excellence in the region and is an example of our activities of which we are particularly proud. Until 2027, the Boehringer Ingelheim Foundation will provide the IMB with funds totalling approximately 154 million euros. From fall 2020 until 2027, the State of Rhineland-Palatinate will be contributing 52 million euros.
The first donation of 100 million euros, pledged in 2009, initiated the establishment of an institute for outstanding basic research in the life sciences, whose scientists and equipment meet international criteria for excellence.
The State of Rhineland-Palatinate contributed 50 million euros toward the construction of the IMB research building. Within just 15 months, an institute for basic research in the life sciences was thus established at the University of Mainz which offers optimal conditions for research.
From the very start, IMB's offer of maximum research freedom and excellent financial conditions have proved to be compelling: three internationally leading researchers – Christof Niehrs, René Ketting, and Helle Ulrich – have been successfully recruited as its scientific directors. At the end of 2020, there were 17 teams of scientists at the IMB focusing on three areas of research: epigenetics, developmental biology and genome stability.